Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

SRSF2 (Serine and arginine rich splicing factor 2)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

SRSF2 mutation	Myelodysplastic Syndrome	SRSF2 mutation	Myelodysplastic Syndrome	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2	ruxolitinib Sensitive: A2 - Guideline ruxolitinib Sensitive : A2
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B	lenalidomide Sensitive: B - Late Trials lenalidomide Sensitive : B
NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	NPM1 mutation + SRSF2 mutation + FLT3-ITD mutation+ DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
NPM1 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	NPM1 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	SRSF2 mutation + DNMT3A mutation + ASXL1 mutation + NRAS mutation	Acute Myelogenous Leukemia	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3	cytarabine + idarubicin Sensitive: C3 – Early Trials cytarabine + idarubicin Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3	LY3009120 Resistant: C3 – Early Trials LY3009120 Resistant : C3
IDH2 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	IDH2 mutation + SRSF2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3	AZD1775 Sensitive: C3 – Early Trials AZD1775 Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3	ACR-368 Sensitive: C3 – Early Trials ACR-368 Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
SRSF2 mutation	Myelodysplastic Syndrome	SRSF2 mutation	Myelodysplastic Syndrome	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3	venetoclax Sensitive: C3 – Early Trials venetoclax Sensitive : C3
SRSF2 mutation	Acute Myelogenous Leukemia	SRSF2 mutation	Acute Myelogenous Leukemia	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D	TP-0903 Resistant: D – Preclinical TP-0903 Resistant : D